Ralimetinib(Synonyms: LY2228820)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Ralimetinib (Synonyms: LY2228820)

Ralimetinib (LY2228820) 是一种有效、选择性、ATP-竞争性的 p38 MAPK α/β 抑制剂,IC50 值分别为 5.3 和 3.2 nM。Ralimetinib (LY2228820) 选择性地抑制 MK2 (Thr334) 磷酸化,但对 p38α MAPK,JNK,ERK1/2,c-Jun,ATF2 或 c-Myc 的磷酸化水平无作用。

Ralimetinib(Synonyms: LY2228820)

Ralimetinib Chemical Structure

CAS No. : 862505-00-8

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Ralimetinib 的其他形式现货产品:

Ralimetinib dimesylate

生物活性

Ralimetinib (LY2228820) is a potent and selective, ATP-competitive inhibitor of p38 MAPK α/β, with IC50s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38α MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc[1].

IC50 & Target[1]

p38β MAPK

3.2 nM (IC50)

p38α MAPK

5.3 nM (IC50)

Clinical Trial

分子量

420.53

Formula

C24H29FN6

CAS 号

862505-00-8

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Campbell RM, et al. Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity. Mol Cancer Ther. 2014 Feb;13(2):364-74.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

发表回复